Inhibitors of bruton's tyrosine kinase
US9926299B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 29, 2013 |
| Grant date | Mar 27, 2018 |
| Priority date | — |
| Expiry date | Jan 21, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D401/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides novel poly-substituted 5-membered heterocyclic compounds represented by Formula (IV), or a pharmaceutically acceptable salt, solvate, metabolite, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as selective irreversible bruton's tyrosine kinase (Btk) inhibitors and are further useful to treat inflammatory, auto immune diseases associated with aberrant B-cell proliferation such as RA (rheumatoid arthritis) and cancers. This invention also provides the preparation of a medicament using of Formula (IV), and methods of preventing or treating diseases associated with excessive Btk activity in mammals, especially humans.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.